Skip to main content
NTRA
NASDAQ Life Sciences

Medicare Covers Signatera MRD Test in Liver Cancer, Opening New Surveillance Market

Tom Rudovsky · Reported by BusinessWire
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$380.77
Mkt Cap
$54.619B
52W Low
$181
52W High
$437.408
52W Position info
110% above low
Off High info
13% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

NTRA has more than doubled off its 52-week low of $181.

Summary

CMS's MolDX program will now pay for serial Signatera testing in hepatocellular carcinoma surveillance for early-stage patients with no evidence of disease after surgery. That is a new reimbursed indication for the company's fastest-growing franchise, and HCC is the most common primary liver cancer, with more than 42,000 new U.S. liver cancer cases expected in 2026. The decision rests on a 125-patient real-world study in JCO Precision Oncology where Signatera showed 83% sensitivity versus 42% for AFP at 100% specificity, with lead time up to 16.5 months ahead of imaging (median 7.9 months) versus 2.2 months for AFP. It extends a run of Signatera wins — Japan PMDA approval in September, the AFT-70 Phase III trial launch in October, and FDA Breakthrough designation for the MCED assay — and follows Q2 revenue of $752.8M, up 38%, with oncology volumes up 57%. Coverage removes the payer hurdle for a surveillance use case that recurs over years, so the revenue effect builds through 2027 rather than landing in one quarter.

At the time of this announcement, NTRA was trading at $380.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $54.6B. The 52-week trading range was $181.00 to $437.41. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

NTRA - Latest Insights

NTRA
Nov 06, 2026, 11:25 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $316.02
Real-time Price: $289.30 info
Change: -$26.72 (-8%) info
Market Cap: $41.684B info
NTRA
Nov 05, 2026, 4:49 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $293.97
Real-time Price: $289.30 info
Change: -$4.67 (-2%) info
Market Cap: $41.684B info
NTRA
Nov 05, 2026, 4:06 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $366.75
Real-time Price: $289.30 info
Change: -$77.45 (-21%) info
Market Cap: $41.684B info
NTRA
Nov 05, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $363.76
Real-time Price: $289.30 info
Change: -$74.46 (-20%) info
Market Cap: $41.684B info
NTRA
Oct 09, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $391.54
Real-time Price: $289.30 info
Change: -$102.24 (-26%) info
Market Cap: $41.684B info